This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okopien, B. Articles by Herman, Z. S. Search for Related Content PubMed PubMed Citation Articles by Okopien, B. Articles by Herman, Z. S. Related Collections Lipid Cardiovascular Endocrinology Metabolism

Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance

Boguslaw Okopie, Robert Krysiak and Zbigniew S. Herman

Department of Clinical Pharmacology, Medical University of Silesia, PL 40-752 Katowice, Poland

Address all correspondence and requests for reprints to: Robert Krysiak, Department of Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland. E-mail: r.krysiak{at}pharmanet.com.pl.

Context: Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR) activators (fibrates) produce many other favorable effects that may contribute to their clinical effectiveness in dyslipidemic and diabetic patients.

Objective: The objective of this study was to compare the impact of a short-term treatment with fenofibrate and the American Heart Association (AHA) step 1 diet on systemic inflammation, hemostasis, and monocyte secretory function in relationship with their metabolic actions.

Design, Setting, Participants, and Interventions: This was a prospective, randomized, placebo-controlled trial involving the group of 91 ambulatory patients with impaired glucose tolerance (IGT) (diagnosed on the basis of the American Diabetes Association criteria), randomly divided into three groups, simultaneously treated for 30 d with the AHA step 1 diet (n = 30), micronized fenofibrate (267 mg/d, n = 31), or placebo (n = 30). The control group included 34 age-, sex-, and weight-matched subjects with normal glucose tolerance. Eighty-six (95%) patients and all control subjects completed the study.

Main Outcome Measures: Plasma markers of inflammation and hemostasis and monocyte release of proinflammatory cytokines were measured.

Results: Compared with subjects with normal glucose tolerance, IGT patients exhibited higher plasma levels/activities of fibrinogen, factor VII, plasminogen activator inhibitor-1, high-sensitivity C-reactive protein, and oxidized low-density lipoproteins. Lipopolysaccharide-activated monocytes from IGT patients released significantly more TNF-, IL-1ß, IL-6, and monocyte chemoattractant protein-1 in comparison with monocytes from control subjects. Thirty-day treatment with fenofibrate but not with the AHA step 1 diet: 1) improved lipid/lipoprotein profile and glucose metabolism, and 2) reversed or alleviated all the above-mentioned abnormalities. The favorable effects of fenofibrate on plasma high-sensitivity C-reactive protein and on monocyte release of TNF-, IL-1ß, IL-6, and monocyte chemoattractant protein-1 did not correlate with its action on plasma lipids but was related to the improvement in insulin sensitivity and weakly to free fatty acid-lowering action.

Conclusions: Our study is the first to show that relatively small disturbances in glucose metabolism are associated with marked and multidirectional abnormalities in plasma markers of inflammation and hemostasis and in monocyte secretory function. Moreover, fenofibrate may exhibit early pleiotropic effects in patients with IGT.

This article has been cited by other articles:

				M. Pruski, R. Krysiak, and B. Okopien Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia Diabetes Care, August 1, 2009; 32(8): 1421 - 1424. [Abstract] [Full Text] [PDF]

				P. Dandona Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342. [Abstract] [Full Text] [PDF]

				R. S. Rosenson, D. A. Wolff, A. L. Huskin, I. B. Helenowski, and A. W. Rademaker Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome Diabetes Care, August 1, 2007; 30(8): 1945 - 1951. [Abstract] [Full Text] [PDF]

				T.-J. Wu, H.-Y. Ou, C.-W. Chou, S.-H. Hsiao, C.-Y. Lin, and P. C. Kao Decrease in Inflammatory Cardiovascular Risk Markers in Hyperlipidemic Diabetic Patients Treated with Fenofibrate Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 158 - 166. [Abstract] [Full Text] [PDF]

				S. Zhu, G. Su, and Q. H. Meng Inhibitory Effects of Micronized Fenofibrate on Carotid Atherosclerosis in Patients with Essential Hypertension Clin. Chem., November 1, 2006; 52(11): 2036 - 2042. [Abstract] [Full Text] [PDF]